Idrofos
Idrofos (Ibandronate 150 mg) — Sun Pharma monthly oral bisphosphonate for osteoporosis and bone metastases. Strict empty-stomach upright-30-min dosing rule.
✓ Zweryfikowany medycznie przez Morgan Ellis — Badacz farmaceutyczny · 8 lat doświadczenia · Ostatnia weryfikacja: maj 2026
Szybka odpowiedź
Idrofos — Ibandronate 150 mg (Sun Pharma). Bisphosphonate — for cancer-related bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia, Paget’s disease, and severe osteoporosis. oral.
Co otrzymujesz z MedsBase:
- producenta certyfikowanego przez WHO-GMP
- Dyskretne opakowanie w zwykłej kopercie
- Wysyłka na cały świat
- Ocenione przez ponad 1400 klientów (przeczytaj opinie)
📦 Gwarancja Ponownej Wysyłki: jeśli Twoje zamówienie nie dotrze w ciągu 20 dni roboczych od wysyłki, wysyłamy je ponownie bez dodatkowych kosztów. Zapoznaj się z polityką.
Dlaczego warto zamawiać z MedsBase
Idrofos ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
All bisphosphonates carry ONJ risk — higher with IV agents (zoledronic acid, ibandronate IV) and longer cumulative therapy. Pre-treatment dental review is mandatory; complete invasive dentistry before starting. Avoid invasive dental procedures during therapy if possible. Notify dentist about bisphosphonate use lifelong (effects persist years after stopping).
Bisphosphonates are renally cleared. Adequate hydration before/during IV administration. Monitor renal function and serum calcium. Hypocalcaemia is common; supplement with calcium + vitamin D throughout therapy. Avoid in CrCl <30 (oral) or <35 (IV).
Take first thing in the morning with a full glass (200 mL) of plain water — NO food, drink, or other medications. Remain upright (sitting or standing) for at least 30-60 minutes after the dose to prevent oesophagitis and oesophageal stricture. Then have breakfast and any other medications.
Najczęściej zadawane pytania
When is this used?
Bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia (zoledronic acid IV is fastest), Paget’s disease, and severe osteoporosis (especially adjuvant during AI therapy in breast cancer).
IV vs oral?
IV (zoledronic acid 4 mg q3-4 weekly for cancer; q12 monthly for osteoporosis; ibandronate 6 mg q3-4 weekly): more potent, fewer doses, no GI absorption issues. Oral (ibandronate 150 mg monthly): convenient, no IV access needed, but oesophagitis risk and absorption issues.
ONJ — how worried should I be?
ONJ is rare but cumulative. Risk factors: invasive dental procedures (extraction, implants), poor dental hygiene, smoking, diabetes, glucocorticoid use. Pre-treatment dental review and ongoing oral hygiene minimise risk. Discuss any planned dental work with your oncology team.
Calcium and vitamin D?
Mandatory throughout bisphosphonate therapy: calcium 1000-1500 mg/day plus vitamin D 800-1000 IU/day. Reduces hypocalcaemia risk and improves bone density.
Interakcje lekowe?
Calcium, magnesium, aluminium-containing antacids, iron, multivitamins reduce absorption (oral) — separate by ≥30 minutes. NSAIDs + bisphosphonates: increased GI risk. Aminoglycosides + bisphosphonates: increased nephrotoxicity.
Ciąża?
Long half-life in bone (years to decades). Generally avoided in pre-menopausal women without effective contraception. Limited human pregnancy data.
Co zrobić, jeśli pominię dawkę?
Oral monthly: take next morning if remembered the same week; if missed entirely, return to the original schedule next month. IV: scheduled by specialist; reschedule with oncology team.
Atypical femoral fracture?
Rare class effect after long-term use (typically >5 years osteoporosis use). Drug holiday at 3-5 years considered in osteoporosis. Cancer use typically continues based on disease state.
Acute phase reaction?
Common after first IV bisphosphonate dose: fever, myalgia, arthralgia, fatigue 1-3 days post-infusion. Usually mild, paracetamol-responsive, less severe with subsequent doses.
Stopping?
Specialist-determined based on disease, response, toxicity. Bisphosphonate effect on bone persists for years after stopping due to bone deposition.
Other Cancer & Bone-Health Medications
- Zoldria — zoledronic acid IV — for bone mets and hypercalcaemia
- Bandrone — ibandronate — alternative bisphosphonate
- Idrofos — ibandronate 150 mg monthly oral
- Osteofos — alendronate weekly — for osteoporosis
- Calcirol — vitamin D3 60,000 IU sachet — for adequacy
More options in Anti Cancer Medication
Ranking według liczby ostatnich zamówień MedsBase — co wybierają inni klienci w tej kategorii.
| Moc | 150 mg |
|---|---|
| Ilość | 1 Tablet/s, 3 Tablet/s, 6 Tablet/s |
| Postać farmaceutyczna | Tabletka/s |
| Producent | Sun Pharma |
| Leczenie | Osteoporosis |
| Marka generyczna | Ibandronic Acid |
Idrofos
Pytania i odpowiedzi
Idrofos
Produkty powiązane
Opinie
Nie ma jeszcze opinii